Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 12/20 | 0.63 |
| ▸ | PDE9A | O76083 | 8/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31548661 | 1.00 | PDE2A (0.63) | PDE2APDE9A | |
| SCHEMBL23991845 | 0.91 | PDE2A (0.76) | PDE2APDE9A | |
| SCHEMBL20339600 | 0.77 | PDE2A (1.00) | PDE2APDE9A | |
| SCHEMBL20339516 | 0.77 | PDE2A (1.00) | PDE2APDE9A | |
| SCHEMBL20339563 | 0.77 | PDE2A (1.00) | PDE2APDE9A | |
| SCHEMBL18282864 | 0.75 | PDE2A (0.77) | PDE2A | |
| SCHEMBL18283205 | 0.75 | PDE2A (0.77) | PDE2A | |
| SCHEMBL18282863 | 0.75 | PDE2A (0.77) | PDE2A | |
| SCHEMBL30209342 | 0.75 | PDE9A (0.42) | PDE2APDE9A | |
| SCHEMBL20339988 | 0.74 | PDE2A (0.71) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562828-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-11999738-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | DART NEUROSCIENCE, LLC (US) | 2024-06-04 | — | — | US | disclosed |
| US-20210340145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2021-11-04 | — | — | US | disclosed |
| US-10981916-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | DART NEUROSCIENCE, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200148685-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3562828-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Dart NeuroScience LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018125810-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999738-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, PDE3B | PDE2A 2/4885PDE9A 11/4885 |
| US-20210340145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE3B | PDE2A 2/4885PDE9A 11/4885 |
| US-10981916-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, TDP2 | PDE2A 2/4885PDE9A 11/4885 |
| US-20200148685-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, TDP2 | PDE2A 2/4885PDE9A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.